Dermatology
ASLAN reports interim data from atopic dermatitis drug trial
Singapore-based biopharmaceutical company ASLAN Pharmaceuticals has announced positive interim data from its Phase II TREK-DX study of eblasakimab, a drug…
Changing epidemiology of atopic dermatitis in South Korea
The epidemiology of atopic dermatitis (AD) is heterogeneous across countries and age groups. Traditionally, AD in South Korea has always…
Pipeline Moves: Pfizer’s flu vaccine approval chances rise after Phase III completion
This week on Pipeline Moves, we kick off by looking at a Phase III trial completion of Pfizer’s influenza vaccine…
ARS gears up for neffy US approval
ARS Pharmaceuticals expects to launch neffy (epinephrine nasal spray) in H2 2024, for which the company plans to submit a…
Female vitiligo patients are at an increased risk of osteoporosis
Previously in the literature, an association between those with vitiligo and an increased risk of developing osteoporosis has been speculated.…
Aquestive maps out FDA approval for sublingual anaphylaxis drug
Aquestive Therapeutics has revealed topline data from the Phase III pharmacokinetic (PK) study of its anaphylactic drug, Anaphylm (epinephrine) sublingual…
Sanofi’s amlitelimab shows best-in-class response in atopic dermatitis
Sanofi has announced encouraging findings from the second part of a study with the OX40 antibody amlitelimab, which showed sustained…
Lilly’s eczema drug shows improvement in people with darker skin tones
Eli Lilly has released results from the Phase III Admirable trial of its monoclonal antibody, lebrikizumab, in patients with darker…
J&J’s JNJ-2113 offers high skin clearance rates in psoriasis trial
Johnson & Johnson (J&J) has reported initial findings from the Phase IIb FRONTIER 2 clinical trial, where JNJ-2113 offered high…
Alphyn gears up for Phase IIb trial for dermatitis treatment
Maryland-based Alphyn Biologics announced that the second cohort in its Phase IIa trial evaluating zabalafin hydrogel (AB-101a) in AD and…
